Diabetes Drug Might Also Help Treat Heart

New Post Public Reply Private Reply Replies (1) Message Board

Sep 28, 2018 at 12:53 AM 292

Quote:

Diabetes Drug Might Also Help Treat Heart Disease

Researchers say the drug trodusquemine has the potential to reduce arterial fat and perhaps reverse atherosclerosis.

Can an experimental diabetes drug change how we treat heart disease?

In a new study, researchers tout the drug trodusquemine’s ability to “melt away” arterial fat in preclinical trials involving mice.

The research, conducted at the University of Aberdeen in Scotland, is the first of its kind to demonstrate the drug’s ability to reverse atherosclerosis — in some cases with as little as one dose.

“We could show that using the drug chronically, once a week for five weeks or just once toward the end of the study, both resulted in significantly lower atherosclerotic plaque area. It also lowered serum lipids (triglycerides and cholesterol),” Mirela Delibegovic, a study author and a professor in diabetic medicine at the University of Aberdeen, told Healthline.

Mice in the study were treated with either saline (for the control group), a single trodusquemine dose, or multiple doses.

For mice receiving single or multiple doses, there was a decrease in the measured plaque formation while the control group remained unchanged.

The study at Aberdeen is exciting because, in Delibegovic's words, “[The drug] seemed to completely reverse the effects of” atherosclerosis.

Tackling a major killer

https://www.healthline.com/health-news/diabet...-disease#1
Written by Gigen Mammoser on November 21, 2017

Heart disease is the leading cause of death for both men and women in the United States, according to the Centers for Disease Control and Prevention (CDC).

An estimated 610,000 people die per year from heart disease in the United States, accounting for roughly 25 percent of all deaths annually.

Additionally, more than 700,000 Americans will have a heart attack each year.

Atherosclerosis, the narrowing of arteries caused by a buildup of fatty plaque, is a leading cause of heart attack and stroke.

While the condition is present in all people to some degree, it gets worse as you get older.

It can be affected by many lifestyle factors, including diet, activity level, and smoking.

Atherosclerosis slows blood flow to and from the heart, leading to coronary heart disease, angina, and other, more severe, health complications.

Occlusion, the blocking of a blood vessel, can result in serious, sometimes fatal cardiac incidents. Plaque can also dislodge from the blood vessel resulting in a blood clot (thrombosis).

How the drug works

Trodusquemine works by inhibiting PTP1B, an enzyme in the body that has a role in insulin regulation.

Researchers have previously concluded that the drug is effective in correcting obesity-induced insulin resistance, suppressing appetite, and helping with weight loss.

It may also help in treating diabetes — which makes the drug’s potential even more intriguing.

“Cardiovascular disease is the most prevalent cause of mortality in diabetic patients, due to accelerated atherosclerosis. Thus drugs that could improve both the diabetic status and decrease atherosclerotic progression may hold promise for future therapies,” said Delibegovic.

There is also a strong connection between diabetes, heart disease, and atherosclerosis.

Being able to treat obesity, diabetes, and atherosclerosis with one drug would be groundbreaking.

Atherosclerosis is considered a chronic, low-level inflammatory disease, which is accelerated by diabetes.

Prior studies showed that diabetes worsened atherosclerosis. In 2008, a study from the University of Rochester identified the biological mechanisms for why this occurred.

“We have known for a number of years that inhibition of the protein PTP1B should result in positive outcomes on whole-body insulin sensitivity. We have now added to the evidence that it is also positive in regards to atherosclerosis development,” said Delibegovic.

Future research

At this point, trodusquemine is in early clinical trials for the treatment of diabetes and breast cancer.

Further studies will be required to test whether or not the drug’s ability to reverse atherosclerosis is possible in humans.

Delibegovic and her colleagues are looking forward to continuing their research on the drug.

She says they are currently applying for funding to conduct human trials.

“We plan to continue our research moving onto the human setting now that we have the positive preclinical data,” Delibegovic said.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

PathoSearch: A New Era in Pathology With Visual Search

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Jari Spirits Set to Shake Up U.S. Market After Big Wins

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

IASLC Boosts Global Thoracic Cancer Collaboration

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Nocpix Unveils ACE 2 Thermal Riflescope Lineup

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...